National Bank of Canada FI Has $11.10 Million Position in Elanco Animal Health Incorporated (NYSE:ELAN)

National Bank of Canada FI lifted its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 331.6% during the 4th quarter, HoldingsChannel.com reports. The firm owned 758,000 shares of the company’s stock after buying an additional 582,355 shares during the period. National Bank of Canada FI’s holdings in Elanco Animal Health were worth $11,097,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Raymond James & Associates raised its holdings in Elanco Animal Health by 210.9% during the third quarter. Raymond James & Associates now owns 1,015,294 shares of the company’s stock valued at $11,412,000 after buying an additional 688,779 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its holdings in shares of Elanco Animal Health by 76.8% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 206,210 shares of the company’s stock valued at $2,318,000 after acquiring an additional 89,576 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Elanco Animal Health by 7.2% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,848,934 shares of the company’s stock valued at $20,782,000 after acquiring an additional 124,225 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Elanco Animal Health by 25.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 97,553 shares of the company’s stock valued at $1,096,000 after acquiring an additional 20,053 shares in the last quarter. Finally, Advisor Partners II LLC lifted its holdings in Elanco Animal Health by 409.4% in the 3rd quarter. Advisor Partners II LLC now owns 78,899 shares of the company’s stock worth $887,000 after purchasing an additional 63,411 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Analyst Upgrades and Downgrades

ELAN has been the topic of a number of recent analyst reports. The Goldman Sachs Group lifted their price target on shares of Elanco Animal Health from $12.50 to $14.00 and gave the company a “sell” rating in a research report on Tuesday, February 27th. TheStreet raised shares of Elanco Animal Health from a “d+” rating to a “c-” rating in a research report on Friday, February 23rd. Barclays raised their price target on Elanco Animal Health from $18.00 to $19.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. Finally, Morgan Stanley boosted their price objective on Elanco Animal Health from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $16.71.

Insider Activity

In related news, Director R David Hoover purchased 20,000 shares of the stock in a transaction on Wednesday, March 6th. The shares were purchased at an average cost of $16.14 per share, with a total value of $322,800.00. Following the acquisition, the director now directly owns 185,000 shares in the company, valued at $2,985,900. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.57% of the company’s stock.

Elanco Animal Health Price Performance

Shares of ELAN stock opened at $16.88 on Thursday. The firm has a fifty day moving average of $14.98 and a 200-day moving average of $14.04. The company has a quick ratio of 1.35, a current ratio of 2.75 and a debt-to-equity ratio of 0.92. The firm has a market capitalization of $8.34 billion, a price-to-earnings ratio of -6.75, a price-to-earnings-growth ratio of 1.42 and a beta of 1.34. Elanco Animal Health Incorporated has a 12-month low of $7.88 and a 12-month high of $17.23.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Monday, February 26th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.02). The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1 billion. Elanco Animal Health had a negative net margin of 27.87% and a positive return on equity of 6.44%. The company’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.19 EPS. On average, equities research analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.